Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma (Nasdaq: BBIO) has secured a $300 million upfront payment through a partial monetization of European royalties for BEYONTTRA®, their ATTR-CM treatment. The deal involves selling 60% of royalties on the first $500 million of annual BEYONTTRA European sales to HealthCare Royalty and Blue Owl Capital, with payments capped at 1.45x.
The transaction builds upon BridgeBio's existing partnership with Bayer Consumer Care AG, from which they've already received $210 million in upfront and regulatory milestones, with an additional $75 million in near-term milestone payments expected. The Bayer agreement includes tiered royalties starting in the low-30% range on European net sales.
Clinical data from the ATTRibute-CM study showed significant efficacy, including a 42% reduction in composite ACM and recurrent CVH events at Month 30, and a 50% reduction in cumulative CVH events. The drug is now approved as Attruby in the U.S. and as BEYONTTRA in Europe, Japan, and the UK.
[ "Secured $300 million immediate non-dilutive capital through royalty monetization", "Already received $210 million in upfront and regulatory milestones from Bayer partnership", "Additional $75 million in near-term milestone payments expected", "Clinical trials showed 42% reduction in composite ACM and CVH events", "Achieved 50% reduction in cumulative CVH events in Phase 3 study", "Obtained regulatory approvals across major markets (US, Europe, Japan, UK)", "Structured deal preserves upside potential with 1.45x payment cap" ]BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for July 11, 2025, at 8:00 am ET. The webinar will feature Dr. Matthew Wicklund, a distinguished Professor of Neurology from UT Health Science Center San Antonio, who will discuss limb-girdle muscular dystrophy (LGMD), with a focus on LGMD2I/R9.
The presentation will include insights from Dr. Wicklund, who has extensive experience with over 35 multi-center clinical trials and 200+ publications. Additionally, executive members will provide updates on the BBP-418 program and discuss anticipated Phase 3 interim analysis results expected in H2 2025. The webinar will be accessible through BridgeBio's investor website, with a replay available for 30 days.
BridgeBio Pharma (BBIO) has granted equity awards to 36 new employees in the form of restricted stock units totaling 101,974 shares of common stock. The grants were approved by the compensation committee on May 9, 2025. The vesting schedule includes 25% of shares vesting on May 16, 2026, followed by quarterly vesting of the remaining shares in one-twelfth increments, contingent on continued employment. These inducement grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Clinical outcomes and quality of life measures for acoramidis in variant ATTR-CM - Post-hoc analysis showing lower incidence of atrial fibrillation events - Data on serum TTR levels in both wild-type and variant ATTR-CM patients - Real-world disease progression studies - Analysis of ATTR-CM diagnosis timelines - Mortality cause analysis from the ATTRibute-CM study
The presentations feature research from leading medical institutions including University College London, Stanford University, and the University of Montreal.BridgeBio Pharma (NASDAQ: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference 2025. The company's management team will engage in a fireside chat on Wednesday, May 14 at 2:20 PM PT in Las Vegas, NV.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will remain available for 30 days following the presentation.